Halper Sadeh LLP, an investor rights law firm, is investigating whether the sale of BioDelivery Sciences International, Inc. (NASDAQ: BDSI) to Collegium Pharmaceutical, Inc. for $5.60 per share is fair to BioDelivery shareholders.
Halper Sadeh encourages BioDelivery shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or firstname.lastname@example.org or email@example.com.
The investigation concerns whether BioDelivery and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for BioDelivery shareholders; (2) determine whether Collegium is underpaying for BioDelivery; and (3) disclose all material information necessary for BioDelivery shareholders to adequately assess and value the merger consideration. On behalf of BioDelivery shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.